CAN CSA-Z900 2 2-2012 Tissues for transplantation (Second Edition Update No 1 November 2013).pdf
《CAN CSA-Z900 2 2-2012 Tissues for transplantation (Second Edition Update No 1 November 2013).pdf》由会员分享,可在线阅读,更多相关《CAN CSA-Z900 2 2-2012 Tissues for transplantation (Second Edition Update No 1 November 2013).pdf(34页珍藏版)》请在麦多课文档分享上搜索。
1、CAN/CSA-Z900.2.2-12A National Standard of CanadaTissues for transplantationLegal Notice for StandardsCanadian Standards Association (operating as “CSA Group”) develops standards through a consensus standards development process approved by the Standards Council of Canada. This process brings togethe
2、r volunteers representing varied viewpoints and interests to achieve consensus and develop a standard. Although CSA Group administers the process and establishes rules to promote fairness in achieving consensus, it does not independently test, evaluate, or verify the content of standards.Disclaimer
3、and exclusion of liabilityThis document is provided without any representations, warranties, or conditions of any kind, express or implied, including, without limitation, implied warranties or conditions concerning this documents fitness for a particular purpose or use, its merchantability, or its n
4、on-infringement of any third partys intellectual property rights. CSA Group does not warrant the accuracy, completeness, or currency of any of the information published in this document. CSA Group makes no representations or warranties regarding this documents compliance with any applicable statute,
5、 rule, or regulation. IN NO EVENT SHALL CSA GROUP, ITS VOLUNTEERS, MEMBERS, SUBSIDIARIES, OR AFFILIATED COMPANIES, OR THEIR EMPLOYEES, DIRECTORS, OR OFFICERS, BE LIABLE FOR ANY DIRECT, INDIRECT, OR INCIDENTAL DAMAGES, INJURY, LOSS, COSTS, OR EXPENSES, HOWSOEVER CAUSED, INCLUDING BUT NOT LIMITED TO S
6、PECIAL OR CONSEQUENTIAL DAMAGES, LOST REVENUE, BUSINESS INTERRUPTION, LOST OR DAMAGED DATA, OR ANY OTHER COMMERCIAL OR ECONOMIC LOSS, WHETHER BASED IN CONTRACT, TORT (INCLUDING NEGLIGENCE), OR ANY OTHER THEORY OF LIABILITY, ARISING OUT OF OR RESULTING FROM ACCESS TO OR POSSESSION OR USE OF THIS DOCU
7、MENT, EVEN IF CSA GROUP HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, INJURY, LOSS, COSTS, OR EXPENSES.In publishing and making this document available, CSA Group is not undertaking to render professional or other services for or on behalf of any person or entity or to perform any duty owed b
8、y any person or entity to another person or entity. The information in this document is directed to those who have the appropriate degree of experience to use and apply its contents, and CSA Group accepts no responsibility whatsoever arising in any way from any and all use of or reliance on the info
9、rmation contained in this document. CSA Group is a private not-for-profit company that publishes voluntary standards and related documents. CSA Group has no power, nor does it undertake, to enforce compliance with the contents of the standards or other documents it publishes. Intellectual property r
10、ights and ownershipAs between CSA Group and the users of this document (whether it be in printed or electronic form), CSA Group is the owner, or the authorized licensee, of all works contained herein that are protected by copyright, all trade-marks (except as otherwise noted to the contrary), and al
11、l inventions and trade secrets that may be contained in this document, whether or not such inventions and trade secrets are protected by patents and applications for patents. Without limitation, the unauthorized use, modification, copying, or disclosure of this document may violate laws that protect
12、 CSA Groups and/or others intellectual property and may give rise to a right in CSA Group and/or others to seek legal redress for such use, modification, copying, or disclosure. To the extent permitted by licence or by law, CSA Group reserves all intellectual property rights in this document.Patent
13、rightsAttention is drawn to the possibility that some of the elements of this standard may be the subject of patent rights. CSA Group shall not be held responsible for identifying any or all such patent rights. Users of this standard are expressly advised that determination of the validity of any su
14、ch patent rights is entirely their own responsibility.Authorized use of this documentThis document is being provided by CSA Group for informational and non-commercial use only. The user of this document is authorized to do only the following:If this document is in electronic form:sLOADTHISDOCUMENTON
15、TOACOMPUTERFORTHESOLEPURPOSEOFREVIEWINGITsSEARCHANDBROWSETHISDOCUMENTANDsPRINTTHISDOCUMENTIFITISIN0$(ii) Clostridium; and(iii) Streptococcus pyogenes (group A strep.); and(b) for skin tissue:(i) Staphylococcus aureus;(ii) Streptococcus pyogenes (group A strep.);(iii) Enterococcus sp.;(iv) gram negat
16、ive bacilli;(v) Clostridium; and(vi) fungi (yeasts, moulds).14.3.2.3 Blood cultures14.3.2.3.1 The results of any blood cultures performed shall be documented in the donor record and the medical director shall assess the suitability of the donation. 14.3.2.3.2 The protocol for blood cultures shall be
17、 documented in the SOP manual.14.3.2.4 Transplantation prior to receipt of culture resultsIn situations where tissue transplantation is performed for medical reasons before culture results are available (e.g., fresh osteochondral allografts, which, because of tissue viability issues, must be transpl
18、anted promptly), the culture results shall be forwarded to the transplanting physician as soon as they become available and these results shall be documented in the donor record.The tissue bank shall document the established protocol in its SOPs.14.3.2.5 Evaluation of data14.3.2.5.1 The medical dire
19、ctor or designate shall review the results of all cultures for each tissue. Evaluation of the safety of that tissue shall be determined before the tissue is released for transplantation. The medical director or designate shall document the suitability of a tissue donor before tissues are released. 1
20、4.3.2.5.2 Tissues failing to meet the suitability criteria outlined in the SOP manual shall not be used.14.3.2.5.3 The criteria used for evaluating culture results shall be documented in the SOP manual.9(Replaces p. 9, December 2012)CAN/CSA-Z900.2.2-12 2012 CSA GroupNovember 201314.3.2.6 Repeated mi
21、crobial testing 14.3.2.6.1 For each preparation step in which tissue is unwrapped and rewrapped, a bacteriological culture shall be taken to rule out contamination during the procedure, unless the tissue is processed using a validated sterilization method. Any occurrence of contamination shall be do
22、cumented in the donor record.14.3.2.6.2 The protocol for microbial testing shall be documented in the SOP manual.14.3.2.7 Bacteriological quality control testing prior to release for transplant14.3.2.7.1 Representative microbiological cultures shall be obtained for all tissues to be released for hum
23、an transplantation, unless the release is based on sterilization parameters having been met in accordance with a validated process. The results of aerobic and anaerobic cultures shall be documented in the donor record.14.3.2.7.2 The medical director or designate shall evaluate the data specified in
24、Clause 14.3.2.7.1 before tissue is released for transplantation.14.3.2.7.3 If final culture results are positive, the tissue shall be discarded, except for skin tissue where the culture results identify normal skin flora. 14.3.2.8 Bacteriological testing at time of transplantation14.3.2.8.1 In the a
- 1.请仔细阅读文档,确保文档完整性,对于不预览、不比对内容而直接下载带来的问题本站不予受理。
- 2.下载的文档,不会出现我们的网址水印。
- 3、该文档所得收入(下载+内容+预览)归上传者、原创作者;如果您是本文档原作者,请点此认领!既往收益都归您。
下载文档到电脑,查找使用更方便
10000 积分 0人已下载
下载 | 加入VIP,交流精品资源 |
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- CANCSAZ900222012TISSUESFORTRANSPLANTATIONSECONDEDITIONUPDATENO1NOVEMBER2013PDF

链接地址:http://www.mydoc123.com/p-591369.html